To read the full story, subscribe or sign in.

SK Biopharmaceuticals and Ubix to develop cancer treatments using targeted protein degradation

April 21, 2022

South Korean companies Ubix Therapeutics Inc. and SK Biopharmaceuticals Co. Ltd. are partnering to develop targeted protein degradation cancer therapies.

BioWorld Deals and M&A Cancer Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for Nov. 25, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 25, 2024.

J&J’s Ottava robotic system approved for US pivotal trial

BioWorld MedTech

Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

Upgrade your daily dose of biopharma and medtech news

SK Biopharmaceuticals and Ubix to develop cancer treatments using targeted protein degradation